Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Clearmind Medicine Inc
(NQ:
CMND
)
1.690
+0.040 (+2.42%)
Streaming Delayed Price
Updated: 11:03 AM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Clearmind Medicine Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit Sponsored by Greenberg Traurig Tel Aviv
February 14, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
February 08, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
EXCLUSIVE: Next-Generation Psychedelics, MEAI - The Road Ahead
February 01, 2023
(Part four of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction
Via
Benzinga
Israeli Biotech Develops Ketamine Analogue To Treat Major Depression With Promising Results
January 31, 2023
Israeli-based psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) and partners Bar-Ilan University and Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center have obtained...
Via
Benzinga
Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound
January 31, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
January 25, 2023
Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First?
Via
Benzinga
Hebrew University' Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023
January 25, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
January 25, 2023
It's time to start off the day with an overview of the biggest pre-market stock movers traders need to know about on Wednesday!
Via
InvestorPlace
EXCLUSIVE: Next-Generation Psychedelics, MEAI - What And When
January 24, 2023
(Part three of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction
Via
Benzinga
EXCLUSIVE: Next-Generation Psychedelics, MEAI - How And Why, An Israeli Scientist Explains
January 23, 2023
(This is part two of a four-part series) Check out part one in the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction
Via
Benzinga
Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction
January 20, 2023
(Part one of a four-part series) Increasing evidence of psychedelics’ potential for benefiting both mental and physical health conditions are moving biotech companies and scientists in the sector to...
Via
Benzinga
Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects
January 19, 2023
Psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem.
Via
Benzinga
Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum
January 19, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Envisioning A Cocaine-Addiction Treatment: This Next-Gen Psychedelic Shows Positive Results
January 18, 2023
Israel-based psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) shared additional positive results on the impact of the MEAI molecule in the natural reward process in an in-vivo preclinical...
Via
Benzinga
Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment
January 17, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial
January 10, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
This Original Psychedelic-Based Obesity Treatment Set To First-In-Human Trials
January 06, 2023
Psychedelics biopharma company Clearmind Medicine Inc. (NASDAQ: CMND) and clinical-stage firm SciSparc Ltd.
Via
Benzinga
Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial
January 05, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Israel-Based Clearmind Medicine Inc. CEO Discusses the Potential of Psychedelics for Addiction Treatment in Audio Interview with SmallCapVoice.com
January 04, 2023
Via
ACCESSWIRE
What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways
January 03, 2023
What a year for psychedelics!
Via
Benzinga
Clearmind Medicine Inc.’s Psychedelic-Based Therapeutics Are Revolutionary To The Pharmaceutical Sector; Treating AUD In The Crosshairs ($CMND)
January 03, 2023
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Clearmind Medicine Inc. Positions To Deliver A First-To-Market Psychedelic-Based Treatment For AUD ($CMND)
December 29, 2022
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Clearmind Medicine Announces Shareholders Meeting Results
December 29, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder
December 28, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Inc. Scores Milestone Patent Issuance To Expedite And Protect Psychedelic-Based Treatment For AUD ($CMND)
December 27, 2022
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Clearmind Medicine Inc's CEO, Dr. Adi Zuloff-Shani
December 22, 2022
Via
ACCESSWIRE
Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute
December 21, 2022
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Inc. Is Disrupting The Pharmaceuticals Landscape; First-To-Market Psychedelic-Based Treatment For AUD In Its Crosshairs ($CMND)
December 21, 2022
Via
AB Newswire
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
December 19, 2022
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed.
Via
Benzinga
Israeli Psychedelics Biotech Shares Latest Advancements, Moves Forward With Addictions Treatment
December 19, 2022
Psychedelics company Clearmind Medicine Inc. (NASDAQ: CMND) aims to bring its proprietary compound, CMND-100, to clinical trials while developing additional proprietary psychedelic compounds for...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.